The number of U.S. measles cases was up 20% for the week ending April 11, making it the second-worst outbreak in nearly 20 years, according to federal health officials. The CDC has reported more than 550 cases of the disease since the start of the year in 20 states. (Reuters)

Patient influencers trust conversations happening on social media networks more than they do websites from pharmaceutical companies. Research from Wego Health found that only 3% of respondents listed pharma company websites as their first destination for information. (MM&M)

Two major financial advisory firms are encouraging Allergan shareholders to vote against a proposal from activist investor Appaloosa. Institutional Shareholder Services and Glass Lewis are backing the drugmaker’s efforts to beat back Appaloosa’s demands for leadership changes. (BioPharmaDive)

Catalent wants a piece of the gene-therapy market. The company said on Monday that it is planning to buy Paragon Bioservices for $1.2 billion. Paragon, which makes complex biopharmaceuticals, is expected to earn more than $200 million in revenue this year. (Reuters)

Senior citizens who don’t have their guard up against scams could also be at risk of developing Alzheimer’s disease. Researchers from Chicago’s Rush University tracked 900 seniors over six years and found that those with a low awareness of scams were more likely to develop Alzheimer’s or other impairments later. (Associated Press)